ITMCTR1900002540尚未招募1 期
Efficacy and safety of Thymosin alpha 1 combined with anti-PD-1 and Apatinib in advanced gastric cancer patients failed to second line treatment:a multi-center,open labelled,randomized,controlled trial
Shanghai Dongfang Hospital0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 —（—）
- 性别
- All
入选标准
- •1. Male or female, aged above 18 years;
- •2. ECOG 0-1;
- •3. Pathological diagonosed of advanced gastric cancer or gastric esophageal junction adenocarcinoma;
- •4. According to iRECIST criteria, there is at least one measurable lesion;
- •5. Atlease 2 weeks apart from local palliative radiotherapy to randomization;
- •6. Advanced gastric cancer failed to 2 or more lines treatment.
排除标准
- •1. Known allergic or untolerant to Apatinib,PD-1 antibody or Thymosin alpha 1;
- •2. Uncontrolled variety syndromes;
- •3. With unsolved adverse event related with PD-1 therapy.
研究者
相似试验
进行中（未招募）
1 期
Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type.metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild typeMedDRA version: 20.0 Level: LLT Classification code 10064049 Term: Lung adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2015-005605-36-ITSCICLONE PHARMACEUTICALS ITALY S.R.L.140
已完成
3 期
The Efficacy and Safety of Ta1 for SepsisSepsisNCT02867267Sun Yat-sen University1,106
已完成
2 期
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant MelanomaMalignant MelanomaNCT00911443sigma-tau i.f.r. S.p.A.488
尚未招募
不适用
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLCResectable Non-Small-Cell Lung CancerNCT06607926Xuanwu Hospital, Beijing40
招募中
3 期
Effect of vitamin B1on septic shock patiensSeptic shock.Severe sepsis with septic shockR65.21IRCT20190602043787N2Mashhad University of Medical Sciences70